Cargando…
Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial
Surgical resection offers the best chance for cure for early stage non-small-cell lung cancer (NSCLC, stage I, II, IIIA), but the 5-year survival rates are only moderate, with systemic relapse being the major cause of death. Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials...
Autores principales: | Boer, R H de, Smith, I E, Pastorino, U, O'Brien, M E R, Ramage, F, Ashley, S, Goldstraw, P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362739/ https://www.ncbi.nlm.nih.gov/pubmed/10188899 http://dx.doi.org/10.1038/sj.bjc.6690241 |
Ejemplares similares
-
Lung metastases from melanoma: when is surgical treatment warranted?
por: Leo, F, et al.
Publicado: (2000) -
Is Repeated Hepatic Resection Justified for Malignancy?
por: Sugarbaker, Paul H.
Publicado: (1991) -
Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy
por: Barrett-Lee, P J, et al.
Publicado: (2000) -
Hepatic resection for hepatocellular carcinoma in the octogenarian: is it justified?
por: Lee, Chao-Wei, et al.
Publicado: (2019) -
Adding pre-emptive anticholinergics to antipsychotics: Is it justified?
por: Chatterjee, Kaushik, et al.
Publicado: (2022)